Risk-stratification models for patients receiving HMA-VEN therapies. Two models available for use include the molecular prognostic risk signature (mPRS) and Mayo Clinic risk-prognostication model. The mPRS utilizes 4 key genes (N/KRAS, FLT3-ITD, and TP53) to characterize patients into higher-benefit (ie, low-risk), intermediate-benefit, and lower-benefit (ie, high-risk) groups. Of note, using this 4-gene model, approximately 40% to 50% of patients will be characterized as higher benefit. The Mayo Clinic risk- prognostication model classifies patients into low, intermediate, and high-risk groups based on the incorporation of molecular and response features. Similar to the mPRS model, approximately 40% of patients are categorized as low risk.